Risk of raised serum creatinine and potassium levels in patients treated with ACEIs or ARBs among type 2 diabetes patients with albuminuria and/or hypertension

2.50
Hdl Handle:
http://hdl.handle.net/10755/150879
Type:
Presentation
Title:
Risk of raised serum creatinine and potassium levels in patients treated with ACEIs or ARBs among type 2 diabetes patients with albuminuria and/or hypertension
Abstract:
Risk of raised serum creatinine and potassium levels in patients treated with ACEIs or ARBs among type 2 diabetes patients with albuminuria and/or hypertension
Conference Sponsor:Sigma Theta Tau International
Conference Year:2011
Author:Chui, Winnie, MN
P.I. Institution Name:Khoo Teck Puat Hospital
Title:Advanced Practice Nurse
[22nd International Nursing Research Congress - Research Presentation] Purpose:
To evaluate the risk of raised serum creatinine and potassium among stage 1 to 3 CKD diabetes patients with albuminuria and/or hypertension who are treated with ACEI/ARBs.
Methods:
Patients with diabetes started on ACEIs or ARBs for treatment of hypertension or albuminuria were assessed at baseline as well as within 4 weeks of initiation/uptitration for serum potassium, creatinine, eGFR and other clinical variables.
Results:
A total of 112 patients with type 2 diabetes (43.75% Stage 1, 36.60% Stage 2, 19.64% Stage 3 CKD) who were treated with ACEI/ARBs were included in the analysis. Mean age was 55.9 years. Mean HbA1c was 8.1%, systolic BP 137.7 mmHg, diastolic BP 73.6 mmHg. 36.6% were normoalbuminuric; 38.4% had microalbuminuria and 25% macroalbuminuria.
Only 4.46% of subjects (total 5, stage 1 CKD: 1; stage 2: 4) had creatinine elevation of > 20% after exposure/dose escalation of ACEI/ARBs. Similarly, only 3.57% had serum potassium > 5.2 mmol/L (total 4, stage 1:2; stage 2:2).
Conclusion:
This study revealed an approximate 4.5% risk of significant elevation of creatinine and 3.6% elevation in potassium associated with ACEI/ARBs use in diabetes patients with Stage 1 to 3 CKD. If confirmed in a larger study, the need for re-evaluation of serum creatinine and potassium within 4 weeks of ACEI/ARB initiation/uptitration in early stage CKD could be reviewed.
Repository Posting Date:
26-Oct-2011
Date of Publication:
17-Oct-2011
Sponsors:
Sigma Theta Tau International

Full metadata record

DC FieldValue Language
dc.typePresentationen_GB
dc.titleRisk of raised serum creatinine and potassium levels in patients treated with ACEIs or ARBs among type 2 diabetes patients with albuminuria and/or hypertensionen_GB
dc.identifier.urihttp://hdl.handle.net/10755/150879-
dc.description.abstract<table><tr><td colspan="2" class="item-title">Risk of raised serum creatinine and potassium levels in patients treated with ACEIs or ARBs among type 2 diabetes patients with albuminuria and/or hypertension</td></tr><tr class="item-sponsor"><td class="label">Conference Sponsor:</td><td class="value">Sigma Theta Tau International</td></tr><tr class="item-year"><td class="label">Conference Year:</td><td class="value">2011</td></tr><tr class="item-author"><td class="label">Author:</td><td class="value">Chui, Winnie, MN</td></tr><tr class="item-institute"><td class="label">P.I. Institution Name:</td><td class="value">Khoo Teck Puat Hospital</td></tr><tr class="item-author-title"><td class="label">Title:</td><td class="value">Advanced Practice Nurse</td></tr><tr class="item-email"><td class="label">Email:</td><td class="value">chui.winnie.kl@alexandrahealth.com.sg</td></tr><tr><td colspan="2" class="item-abstract">[22nd International Nursing Research Congress - Research Presentation] Purpose: <br/>To evaluate the risk of raised serum creatinine and potassium among stage 1 to 3 CKD diabetes patients with albuminuria and/or hypertension who are treated with ACEI/ARBs. <br/>Methods: <br/>Patients with diabetes started on ACEIs or ARBs for treatment of hypertension or albuminuria were assessed at baseline as well as within 4 weeks of initiation/uptitration for serum potassium, creatinine, eGFR and other clinical variables. <br/>Results:<br/>A total of 112 patients with type 2 diabetes (43.75% Stage 1, 36.60% Stage 2, 19.64% Stage 3 CKD) who were treated with ACEI/ARBs were included in the analysis. Mean age was 55.9 years. Mean HbA1c was 8.1%, systolic BP 137.7 mmHg, diastolic BP 73.6 mmHg. 36.6% were normoalbuminuric; 38.4% had microalbuminuria and 25% macroalbuminuria. <br/>Only 4.46% of subjects (total 5, stage 1 CKD: 1; stage 2: 4) had creatinine elevation of &gt; 20% after exposure/dose escalation of ACEI/ARBs. Similarly, only 3.57% had serum potassium &gt; 5.2 mmol/L (total 4, stage 1:2; stage 2:2). <br/>Conclusion:<br/>This study revealed an approximate 4.5% risk of significant elevation of creatinine and 3.6% elevation in potassium associated with ACEI/ARBs use in diabetes patients with Stage 1 to 3 CKD. If confirmed in a larger study, the need for re-evaluation of serum creatinine and potassium within 4 weeks of ACEI/ARB initiation/uptitration in early stage CKD could be reviewed.</td></tr></table>en_GB
dc.date.available2011-10-26T10:45:24Z-
dc.date.issued2011-10-17en_GB
dc.date.accessioned2011-10-26T10:45:24Z-
dc.description.sponsorshipSigma Theta Tau Internationalen_GB
All Items in this repository are protected by copyright, with all rights reserved, unless otherwise indicated.